{"entity":{"id":"adriatic","kind":"trial","name":"ADRIATIC","aka":[],"tldr":"ADRIATIC brought the first improvement in curative-intent small-cell lung cancer treatment in 30 years: a year or two of immunotherapy after chemoradiation lengthens life.","summary":"ADRIATIC, trial NCT03703297 sponsored by AstraZeneca and reported in 2024, brought the first improvement in curative-intent small-cell lung cancer treatment in thirty years: durvalumab consolidation for up to two years after concurrent chemoradiotherapy for limited-stage disease lengthens life. It randomised 730 patients without progression after chemoradiation to durvalumab or placebo and met both primary endpoints of overall and progression-free survival, leading to FDA approval on 4 December 2024, with benefit regardless of prophylactic cranial irradiation. OnCo links it to small-cell lung cancer, modern radiotherapy, prophylactic cranial irradiation, durvalumab, the limited-stage and PCI terms and Corinne Faivre-Finn, and it applies the PACIFIC template to small-cell disease. It is a single pivotal trial, and whether real-world consolidation series reproduce it is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03703297","url":"https://clinicaltrials.gov/study/NCT03703297"},{"label":"FDA approval (Dec 2024)","url":"https://www.onclive.com/view/fda-approves-durvalumab-for-limited-stage-small-cell-lung-cancer"}],"tags":[],"related":[],"cancers":["sclc","limited-stage-sclc"],"sections":[],"technologies":["imrt-igrt","prophylactic-cranial-irradiation"],"targets":[],"drugs":["durvalumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":["limited-extensive-stage","pci-term"],"trials":[],"people":["corinne-faivre-finn"],"bottlenecks":[],"keyPapers":["paper-adriatic-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03703297","phase":"3","setting":"Limited-stage SCLC without progression after concurrent chemoradiotherapy: durvalumab consolidation (up to 2 years) vs placebo","sponsor":"AstraZeneca","result":"OS 55.9 vs 33.4 months, HR 0.73.","started":"2018-09-27","startedType":"actual","yearReported":2024,"enrolled":730,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Durvalumab","n":264,"value":55.9},{"name":"Placebo","n":266,"value":33.4}],"hr":0.73,"ci":[0.57,0.93],"p":"0.0104","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa2404873"},{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Durvalumab","value":16.6},{"name":"Placebo","value":9.2}],"hr":0.76,"ci":[0.61,0.95],"source":"https://doi.org/10.1056/NEJMoa2404873"}],"replication":"Single pivotal trial; consistent with PACIFIC in NSCLC. Real-world consolidation series are emerging."},"route":"/trials/adriatic/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/"},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/"}],"person":[{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/"}],"paper":[{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/"}],"trial":[{"id":"turrisi-intergroup-0096","kind":"trial","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","route":"/trials/turrisi-intergroup-0096/"}]}}